Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021
Positive Results From Trial of Risperidone Injectable Schizophrenia Treatment
Teva's pursuit of J&J boosted by FDA acceptance of filing for approval of long-acting schizophrenia drug | Fierce Pharma
Teva: The Road To Perdition Has Turned Into A Path Towards Redemption (NYSE: TEVA) | Seeking Alpha
Buy Teva Pharmaceuticals amid positive news, Bernstein says
Teva, MedinCell announce positive results for registration trial of TV-46000/mdc-IRM for patients with Schizophrenia - Pharmaceutical Business review
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia | Business Wire
Teva Reports Fourth Quarter and Full Year 2021 Financial Results
Teva Pharm Q4 profit rises, sees more growth in key drugs
Teva Pharmaceutical Stock: Prepare For Takeoff (NYSE:TEVA) | Seeking Alpha
/cloudfront-us-east-2.images.arcpublishing.com/reuters/Q3V76PIRQBKVFCT4F2KKAGPMDE.jpg "Drugmaker Teva may pay as much as $3.6 billion in U.S. opioid settlement | Reuters")
Drugmaker Teva may pay as much as $3.6 billion in U.S. opioid settlement | Reuters
Teva Denied On LAI Risperidone But Expected To Bounce Back 'Quickly' :: Generics Bulletin
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire
FDA declines to approve Teva-MedinCell's risperidone injection for treating schizophrenia | Seeking Alpha
PROPOSAL FOR THE ADDITION OF RISPERIDONE LONG-ACTING INJECTION AND PALIPERIDONE PALMITATE 1-MONTH LONG-ACTING INJECTION FOR THE
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire
Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021
Teva Denied On LAI Risperidone But Expected To Bounce Back 'Quickly' :: Generics Bulletin
Teva Denied On LAI Risperidone But Expected To Bounce Back 'Quickly' :: Generics Bulletin
Risperidone extended-release injectable suspension | MDedge Psychiatry
Teva Upbeat On Risperidone Results :: Generics Bulletin
Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021
Yo-Bio on Twitter: "$TEVA will compete in the risperidone Extended-Release market with $JNJ (risperdal consta- every 2 weeks, INTRAMUSCULAR) and $INDV (PERSERIS- every 4 weeks, subcutaneous). if Teva regimen and efficacy will
Teva, MedinCell Schizophrenia Drug Delayed over FDA Concerns | BioSpace
Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market - Clinical Trials Arena
